SS
TRDA icon

Steve Schonfeld’s Entrada Therapeutics TRDA Stock Holding History

Steve Schonfeld’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-81,411
Closed -$1.16M – 2426
2024
Q2 		$1.16M Buy
81,411
+52,460
+181% +$746K 0.01% 1132
2024
Q1 		$410K Buy
+28,951
New +$409K ﹤0.01% 1544

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Steve Schonfeld's TRDA Position: Q3 2024 in Review

Steve Schonfeld sold out of Entrada Therapeutics (TRDA) in Q3 2024, closing a stake of 81,411 shares — an estimated $1.16M sold.

Steve Schonfeld first reported a position in TRDA in Q1 2024 and held it in 2 quarters. The position peaked at $1.16M in Q2 2024. 97 funds tracked by Wall St. Rank hold TRDA as of Q3 2024.

  • Steve Schonfeld reported no remaining Entrada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Steve Schonfeld sold 81,411 Entrada Therapeutics shares in Q3 2024, an estimated $1.16M.
  • Steve Schonfeld first reported a position in Entrada Therapeutics in Q1 2024 and held it in 2 quarters.
  • Steve Schonfeld's Entrada Therapeutics position peaked at $1.16M in Q2 2024.
  • 97 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.